Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 26 citing articles:

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 93
Trial watch: chemotherapy-induced immunogenic cell death in oncology
Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 45
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Francesco Cortiula, Bart Reymen, Solange Peters, et al.
Annals of Oncology (2022) Vol. 33, Iss. 9, pp. 893-908
Open Access | Times Cited: 65
Clinical applications of plasma proteomics and peptidomics: Towards precision medicine
Bo He, Zhao Huang, Canhua Huang, et al.
PROTEOMICS - CLINICAL APPLICATIONS (2022) Vol. 16, Iss. 6
Closed Access | Times Cited: 40
Methods and clinical biomarker discovery for targeted proteomics using Olink technology
Han Wang, Tian Zhao, Jingjing Zeng, et al.
PROTEOMICS - CLINICAL APPLICATIONS (2024) Vol. 18, Iss. 5
Closed Access | Times Cited: 8
Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma
Long Shu, Jun Tang, Shuang Liu, et al.
Cellular Oncology (2023) Vol. 47, Iss. 2, pp. 555-571
Closed Access | Times Cited: 14
Immunotherapy for lung cancer
Girshani Sathish, L.K. Monavarshini, Keerthi Sundaram, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155104-155104
Closed Access | Times Cited: 6
Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study
Fríða Björk Gunnarsdóttir, Pär‐Ola Bendahl, Alexandra Johansson, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 11
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Giuseppe Lo Russo, Arsela Prelaj, James M. Dolezal, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006833-e006833
Open Access | Times Cited: 10
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
Rianne D.W. Vaes, Francesco Cortiula, Shaowen Lyu, et al.
Lung Cancer (2025), pp. 108541-108541
Open Access
The dual effect of interferon-γ in acute myeloid leukemia: A narrative review
Abiy Ayele Angelo, Gashaw Adane, Dereje Mengesha Berta, et al.
Seminars in Oncology (2025) Vol. 52, Iss. 3, pp. 152347-152347
Open Access
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer
Anaís Sánchez‐Castillo, Elien Heylen, Judith Hounjet, et al.
British Journal of Cancer (2023) Vol. 130, Iss. 4, pp. 568-584
Open Access | Times Cited: 7
Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors
Metin Gunes, Steven T. Rosen, Idit Shachar, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo
Byron Brook, Abhinav Kumar Checkervarty, Soumik Barman, et al.
iScience (2024) Vol. 27, Iss. 11, pp. 111055-111055
Open Access | Times Cited: 2
Trial watch: anticancer vaccination with dendritic cells
Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Distinct roles of CD244 expression in cancer diagnosis and prognosis: A pan-cancer analysis
Zhenzhen Deng, Yuanhong Liu, Haiyan Zhou
Heliyon (2024) Vol. 10, Iss. 7, pp. e28928-e28928
Open Access | Times Cited: 1
Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization
Youpeng Chen, Enzhong Li, Zhenglin Chang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
Jenny Sprooten, An Coosemans, Abhishek D. Garg
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 6
Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer
Yentl Lambrechts, Abhishek D. Garg, Giuseppe Floris, et al.
Genes and Immunity (2023) Vol. 24, Iss. 5, pp. 270-279
Open Access | Times Cited: 3
The mRNA vaccine BNT162b2 demonstrates impaired TH1 immunogenicity in human elders in vitro and aged mice in vivo
Byron Brook, Benoit Fatou, Abhinav Kumar Checkervarty, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 4
Deficiency of salt‐inducible kinase 2 (SIK2) promotes immune injury by inhibiting the maturation of lymphocytes
Jiaojiao Zhu, Chao Li, Ping Wang, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 2
Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor
Simone Stensgaard, Astrid Thomsen, Sofie Helstrup, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5628-5628
Open Access | Times Cited: 2
Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis
Xiaoshuang Feng, David C. Muller, Hana Zahed, et al.
EBioMedicine (2023) Vol. 92, pp. 104623-104623
Open Access | Times Cited: 1
Exploring tumor-normal cross-talk with TranNet: Role of the environment in tumor progression
Bayarbaatar Amgalan, Chi‐Ping Day, Teresa M. Przytycka
PLoS Computational Biology (2023) Vol. 19, Iss. 9, pp. e1011472-e1011472
Open Access | Times Cited: 1
T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma
Peng Ding, Lichao Liu, Yawen Bin, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 23, pp. 7223-7223
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top